Premium
Hybrid Protein Nano‐Reactors Enable Simultaneous Increments of Tumor Oxygenation and Iodine‐131 Delivery for Enhanced Radionuclide Therapy
Author(s) -
Chen Jiawen,
Liang Chao,
Song Xuejiao,
Yi Xuan,
Yang Kai,
Feng Liangzhu,
Liu Zhuang
Publication year - 2019
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201903628
Subject(s) - nanoreactor , tumor hypoxia , glutaraldehyde , hypoxia (environmental) , radionuclide therapy , human serum albumin , biocompatible material , chemistry , cancer therapy , biophysics , materials science , cancer research , cancer , biomedical engineering , biochemistry , medicine , oxygen , nuclear medicine , catalysis , radiation therapy , biology , organic chemistry
It is hard for current radionuclide therapy to render solid tumors desirable therapeutic efficacy owing to insufficient tumor‐targeted delivery of radionuclides and severe tumor hypoxia. In this study, a biocompatible hybrid protein nanoreactor composed of human serum albumin (HSA) and catalase (CAT) molecules is constructed via glutaraldehyde‐mediated crosslinking. The obtained HSA‐CAT nanoreactors (NRs) show retained and well‐protected enzyme stability in catalyzing the decomposition of H 2 O 2 and enable efficient labeling of therapeutic radionuclide iodine‐131 ( 131 I). Then, it is uncovered that such HSA‐CAT NRs after being intravenously injected into tumor‐bearing mice exhibit efficient passive tumor accumulation as vividly visualized under the fluorescence imaging system and gamma camera. As the result, such HSA‐CAT NRs upon tumor accumulation would significantly attenuate tumor hypoxia by decomposing endogenous H 2 O 2 produced by cancer cells to molecular oxygen, and thereby remarkably improve the therapeutic efficacy of radionuclide 131 I. This study highlights the concise preparation of biocompatible protein nanoreactors with efficient tumor homing and hypoxia attenuation capacities, thus enabling greatly improved tumor radionuclide therapy with promising potential for future clinical translation.